EXPERIMENTAL STUDY
Dichloroacetate improves postischemic function of hypertrophied rat hearts
Richard B. Wambolt, BSc*,
Gary D. Lopaschuk, PhD ,
Roger W. Brownsey, PhD and
Michael F. Allard, BSc, MD*
* Department of Pathology and Laboratory Medicine, University of British Columbia, St. Paul’s Hospital, Vancouver, British Columbia, Canada
Cardiovascular Research Group, University of Alberta, Edmonton, Alberta, Canada
Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada
Manuscript received October 26, 1999;
revised manuscript received February 3, 2000,
accepted May 31, 2000.
Reprint requests and correspondence: Dr. Michael F. Allard, McDonald Research Laboratories, Room 292, St. Paul’s Hospital, 1081 Burrard Street, Vancouver, British Columbia, Canada V6Z 1Y6
mallard{at}mrl.ubc.ca
 |
Abstract
|
|---|
OBJECTIVES
We sought to determine whether improving coupling between glucose oxidation and glycolysis by stimulating glucose oxidation during reperfusion enhances postischemic recovery of hypertrophied hearts.
BACKGROUND
Low rates of glucose oxidation and high glycolytic rates are associated with greater postischemic dysfunction of hypertrophied as compared with nonhypertrophied hearts.
METHODS
Heart function, glycolysis and glucose oxidation were measured in isolated working control and hypertrophied rat hearts for 30 min before 20 min of global, no-flow ischemia and during 60 min of reperfusion. Selected control and hypertrophied hearts received 1.0 mmol/liter dichloroacetate (DCA), an activator of pyruvate dehydrogenase, at the time of reperfusion to stimulate glucose oxidation.
RESULTS
In the absence of DCA, glycolysis was higher and glucose oxidation and recovery of function were lower in hypertrophied hearts than in control hearts during reperfusion. Dichloroacetate stimulated glucose oxidation during reperfusion approximately twofold in both groups, while significantly reducing glycolysis in hypertrophied hearts. It also improved function of both hypertrophied and control hearts. In the presence of DCA, recovery of function of hypertrophied hearts was comparable to or better than that of untreated control hearts.
CONCLUSIONS
Dichloroacetate, given at the time of reperfusion, normalizes postischemic function of hypertrophied rat hearts and improves coupling between glucose oxidation and glycolysis by increasing glucose oxidation and decreasing glycolysis. These findings support the hypothesis that low glucose oxidation rates and high glycolytic rates contribute to the exaggerated postischemic dysfunction of hypertrophied hearts.
|
Abbreviations and Acronyms
| | ANOVA | = analysis of variance | | ATP | = adenosine triphosphate | | DCA | = dichloroacetate | | NAD | = oxidized nicotinamide adenine dinucleotide | | NADH2 | = reduced nicotinamide adenine dinucleotide | | PDH | = pyruvate dehydrogenase | | PDK | = pyruvate dehydrogenase kinase | | pHi | = intracellular H+ concentration |
|
Postischemic left ventricular dysfunction is greater in hypertrophied hearts than in nonhypertrophied hearts (1–6). Alterations in myocardial energy metabolism, particularly glucose metabolism, are thought to contribute to the increased susceptibility of hypertrophied hearts to injury after ischemia and reperfusion (1–6). During reperfusion of the hypertrophied heart, glycolysis and oxidation of glucose, fatty acid and lactate recover to preischemic values (3). This finding indicates that impairments in glycolysis and oxidative metabolism are not responsible for the greater postischemic left ventricular dysfunction of hypertrophied as compared with nonhypertrophied hearts.
Although overall energy metabolism is not impaired, the pattern of energy substrate use is altered and may influence postischemic left ventricular function in the hypertrophied heart (3,4). Rates of glycolysis are accelerated in hypertrophied as compared with nonhypertrophied hearts during postischemic reperfusion (3,4). However, rates of glucose oxidation during reperfusion are not correspondingly increased in hypertrophied hearts (3,4). Under normal circumstances, the increased production of pyruvate accompanying accelerated rates of glycolysis should lead to higher rates of glucose oxidation by way of pyruvate-induced activation of pyruvate dehydrogenase (PDH), a key enzyme involved in glucose oxidation in mammalian tissues (7,8). Thus, relative to glycolysis, glucose oxidation is substantially lower than normal in the hypertrophied heart during reperfusion.
These low rates of glucose oxidation result in a dramatic imbalance (or uncoupling) between glycolysis and glucose oxidation in the hypertrophied heart that is much greater than that seen in the nonhypertrophied heart (9,10). In nonhypertrophied hearts, low rates of glucose oxidation and increased uncoupling between glycolysis and glucose oxidation are detrimental during reperfusion after ischemia (9,10). Stimulation of glucose oxidation, which improves coupling between glycolysis and glucose oxidation, is clearly beneficial to the nonhypertrophied heart during reperfusion after ischemia (9–14). Taken together, these data suggest that low rates of glucose oxidation, high glycolytic rates and the accompanying accentuated uncoupling between glycolysis and glucose oxidation are responsible for the increased postischemic dysfunction of hypertrophied as compared with nonhypertrophied hearts.
Therefore, we undertook this study to test the hypothesis that improving coupling between glucose oxidation and glycolysis by stimulating glucose oxidation enhances postischemic function of the hypertrophied heart.
|
Experimental methods
|
|---|
Animal model.
As previously described (3,4,15), a mild pressure overload cardiac hypertrophy was induced in male Sprague-Dawley rats by constriction of the suprarenal abdominal aorta. In control rats, the aorta was isolated but not constricted. Food and water were available as desired. These experiments were approved by the University of British Columbia’s Committee on Animal Care in accordance with guidelines set by the Canadian Council on Animal Care.
Isolated heart preparation.
As described (3,4,15), hearts from halothane-anesthetized rats were perfused as isolated working preparations at a preload of 11.5 mm Hg and an afterload of 80 mm Hg with 100 ml of Krebs-Henseleit solution eight weeks after the operation. The solution, which contained 1.2 mmol/liter palmitate prebound to 3% albumin, 5.5 mmol/liter (5-3H)-glucose (31,838 ± 1,132 disintegrations per minute [dpm]/µmol glucose), (U-14C)-glucose (40,611 ± 1,381 dpm/µmol glucose), 0.5 mmol/liter lactate, 2.5 mmol/liter calcium and 100 mU/liter insulin, continuously circulated through the closed perfusion system. The solution was oxygenated with 95% oxygen and 5% carbon dioxide and maintained at 37°C throughout the perfusion. A high concentration of palmitate was used to recapitulate the levels of fatty acids observed in vivo during ischemia and reperfusion (16).
A pressure transducer (Viggo-Spectramed, Oxnard, California) inserted in the afterload line was used to measure heart rate and peak systolic pressure. Cardiac output and aortic flow were measured by means of external flow probes (Transonic Systems Inc., Ithaca, New York) on the preload and aortic outflow lines, respectively. Coronary flow was calculated as the difference between cardiac output and aortic flow. The external work performed by the heart was expressed as the rate–pressure product (calculated as the product of heart rate and peak systolic pressure) and hydraulic work (calculated as the product of cardiac output and peak systolic pressure) (11,15).
Perfusion protocol.
Spontaneously beating hearts were subjected to 30 min of normoxic, nonischemic perfusion followed by 20 min of global (no-flow) normothermic ischemia and 60 min of normoxic reperfusion. This severity of ischemia was chosen because it maximizes the number of hearts that recover (approximately two-thirds) and reliably causes significant postischemic myocardial dysfunction (30% to 60% of preischemic function). Reperfusion was initiated by unclamping the preload and afterload lines. Perfusate in these lines was replenished throughout the ischemic period. As such, hearts received warm, oxygenated perfusate (with or without dichloroacetate [DCA]) immediately at the onset of reperfusion. When administered, DCA (1.0 mmol/liter) was introduced into the recirculating perfusate 5 min before the end of ischemia to achieve complete mixing before reperfusion. We exclusively determined the effect of DCA on postischemic function when administered only at reperfusion, because not only is this the most clinically relevant situation, but it also has been shown that DCA and insulin are detrimental to postischemic recovery when given together before ischemia (9). The exaggerated dysfunction under these circumstances is likely a consequence of increased proton and lactate accumulation during ischemia (9,12). A subset of this series was perfused nonischemically for 30 min in the presence or absence of 1.0 mmol/liter DCA.
A separate series of control and hypertrophied hearts was also studied in which the hearts were paced electrically (300 beats/min) during reperfusion to account for differences in heart rate. The paced hearts were perfused exactly as the first series, except that glycolysis and glucose oxidation were not measured.
Left ventricular function was measured every 10 min of nonischemic perfusion and at intervals of 5, 10, 15, 20, 40 and 60 min during reperfusion. At the end of the nonischemic and reperfusion periods, the hearts were quickly frozen using tongs cooled to the temperature of liquid nitrogen. The frozen tissue was weighed to determine ventricular weight, powdered and stored at –70°C. The atrial tissue remaining was dried, weighed and used in the calculation of the total heart weight. A portion of the ventricular tissue was dried to determine the dry/wet ratio used in the calculation of the total dry weight of the heart. Glycogen content was determined in representative samples of frozen myocardium by standard techniques.
Measurement of glucose oxidation and glycolysis.
Glycolysis and glucose oxidation rates were determined as previously described (3,4,15). Glycolysis was determined by measuring the rate at which 3H2O was released from (5-3H)-glucose at the triose phosphate isomerase and enolase steps of glycolysis. Glucose oxidation was measured by quantitative collection of 14CO2 liberated from (U-14C)-glucose by mitochondrial pyruvate, isocitrate and oxoglutarate dehydrogenases.
Perfusate and gaseous samples were taken every 10 min of nonischemic perfusion and at intervals of 5, 10, 15, 20, 40 and 60 min during reperfusion. Samples for determination of glycolysis and glucose oxidation were ultimately placed in vials containing scintillation cocktail and counted by standard techniques. Glycolysis and glucose oxidation reflect the metabolism of exogenous glucose, because the contribution of glycogen was not directly measured in these experiments.
Statistical analysis.
Analysis was performed using SPSS version 7.0. Weight data were analyzed using two-way analysis of variance (ANOVA). Left ventricular function, glucose oxidation and glycolysis were examined using two-way repeated measures ANOVA. A log transformation of data was used, when necessary, to satisfy homogeneity of variance assumptions for ANOVA. The sequential rejective Bonferroni procedure was used to correct for multiple comparisons and tests (17). A corrected p value >0.05 was considered as nonsignificant. Data are expressed as the mean value ± SEM.
|
Results
|
|---|
Heart weight and body weight data.
There were no differences in heart weight or body weight between treated and untreated control groups or between treated and untreated aortic-banded groups (data not shown). The heart weight of the aortic-banded rats (2.1 ± 0.1 g, n = 39) was greater than that of the control rats (1.9 ± 0.1 g, n = 34, p < 0.05). Body weight was not different between aortic-banded (488 ± 11 g) and control rats (479 ± 7 g, p = NS).
Mechanical function of control and hypertrophied hearts.
Before ischemia, significant differences were not observed in either series—that is, between control hearts with and without DCA during reperfusion or between hypertrophied hearts with and without DCA during reperfusion (data not shown). In spontaneously beating hearts, all variables of function, except peak systolic pressure, were lower in hypertrophied hearts than in control hearts before ischemia (Table 1, Fig. 1). During reperfusion, all functional variables were lower in untreated, spontaneously beating control and hypertrophied hearts, as compared with corresponding preischemic values (Table 1, Fig. 1). With the exception of hydraulic work and peak systolic pressure, left ventricular functional indexes were lower in untreated hypertrophied hearts than in untreated control hearts during reperfusion (Table 1, Fig. 1).
View this table:
[in this window]
[in a new window]
|
Table 1 Mechanical Function of Spontaneously Beating Control and Hypertrophied Working Rat Heart Reperfused After Ischemia
|
|
Treatment of spontaneously beating control and hypertrophied hearts with DCA during reperfusion improved most functional variables in both groups, as compared with corresponding values in untreated hearts (Table 1, Fig. 1). Heart function and coronary flow increased in DCA-treated hypertrophied hearts to values that were significantly greater than or comparable to those in untreated control hearts (Table 1, Fig. 1). However, hydraulic work and coronary flow were significantly lower in DCA-treated hypertrophied hearts than in DCA-treated control hearts. Exposure of nonischemic hearts to DCA also significantly improved function in both groups (Table 2).
View this table:
[in this window]
[in a new window]
|
Table 2 Mechanical Function and Glucose Metabolism in Spontaneously Beating Nonischemic Control and Hypertrophied Working Rat Hearts
|
|
Mechanical function of control and hypertrophied rat hearts that were paced during reperfusion is summarized in Table 3. The results of this series were very similar to those of the spontaneously beating control and hypertrophied hearts during reperfusion (Table 1). Dichloroacetate improved functional recovery during reperfusion of both control and hypertrophied hearts, as compared with corresponding values in untreated hearts. In the presence of DCA, contractile function during reperfusion of paced hypertrophied hearts was comparable to that seen in untreated, paced control hearts. Except for peak systolic pressure, contractile function of DCA-treated, paced control hearts was significantly greater than that of DCA-treated, paced hypertrophied hearts during reperfusion.
View this table:
[in this window]
[in a new window]
|
Table 3 Mechanical Function of Control and Hypertrophied Working Rat Hearts Paced During Reperfusion After Ischemia
|
|
Myocardial glucose metabolism.
Glycolysis
Rates of glycolysis were accelerated in hypertrophied hearts as compared with control hearts during the preischemic period (Fig. 2). During reperfusion, rates of glycolysis in untreated control and hypertrophied hearts did not differ from corresponding preischemic values. Glycolytic rates were not significantly altered by DCA in control hearts during reperfusion (Fig. 2). However, rates of glycolysis were significantly reduced by DCA during reperfusion in hypertrophied hearts, as compared with values in untreated hypertrophied hearts and in hypertrophied hearts before ischemia (Fig. 2). As during reperfusion, glycolysis was decreased by DCA in nonischemic hypertrophied hearts, but not in nonischemic control hearts (Table 2).
Glucose oxidation
During the preischemic period, rates of glucose oxidation tended to be lower in hypertrophied hearts than in control hearts, but the difference was not significant (Fig. 3). As with glycolytic rates, glucose oxidation rates in untreated control and hypertrophied hearts during reperfusion were not different from corresponding preischemic values (Fig. 3). However, glucose oxidation during reperfusion was significantly depressed in untreated hypertrophied hearts as compared with untreated control hearts (Fig. 3). Glucose oxidation during reperfusion was significantly increased by DCA in both control and hypertrophied hearts, as compared with preischemic values or with values in untreated control and hypertrophied hearts during reperfusion. Glucose oxidation rates during reperfusion in DCA-treated hypertrophied hearts were lower, but not significantly, than rates in DCA-treated control hearts (Fig. 3). Dichloroacetate treatment also increased glucose oxidation nearly twofold in nonischemic control and hypertrophied hearts (Table 2).
Myocardial glycogen.
Glycogen did not differ significantly between control and hypertrophied hearts before ischemia (control 95 ± 4 vs. hypertrophy 101 ± 2 µmol/g dry weight, p = NS). During ischemia, glycogen decreased to comparable values in control and hypertrophied hearts (control 63 ± 5 vs. hypertrophy 64 ± 6 µmol/g dry weight, p = NS). Glycogen was resynthesized to similar but slightly different degrees in all groups during reperfusion (control 100 ± 2 vs. control + DCA 109 ± 2 µmol/g dry weight, p < 0.05; hypertrophy 107 ± 3 vs. hypertrophy + DCA 115 ± 4 µmol/g dry weight, p < 0.05).
|
Discussion
|
|---|
Dichloroacetate, contractile function and glucose oxidation.
The beneficial effects of DCA on functional recovery of nonhypertrophied hearts after ischemia are well described (9–14). The improved postischemic function of nonhypertrophied hearts produced by DCA has been associated with and attributed to a stimulation of glucose (and pyruvate) oxidation (9–14). The current study demonstrates that this association also occurs in the reperfused ischemic hypertrophied heart (Tables 1 and 3, Fig. 1 and 3). Dichloroacetate stimulates glucose oxidation because it activates PDH, a mitochondrial multienzyme complex that oxidatively decarboxylates pyruvate to form carbon dioxide, reduced nicotinamide adenine dinucleotide (NADH2) and acetyl coenzyme A (7,8). The activity of PDH is a major determinant of the extent of myocardial glucose oxidation (7,8). Activity of PDH is regulated by reversible phosphorylation of PDH and by end-product inhibition by acetyl coenzyme A and NADH2 (7,8). Phosphorylation by pyruvate dehydrogenase kinase (PDK) inactivates the PDH complex, whereas dephosphorylation by pyruvate dehydrogenase phosphatase leads to reactivation (7,8). Dichloroacetate activates PDH by inhibiting PDK (18,19), thereby stimulating glucose oxidation.
Dichloroacetate and glycolysis.
In the absence of DCA, rates of glycolysis before and after ischemia were accelerated in hypertrophied as compared with nonhypertrophied hearts (Fig. 2, Table 2)—a finding in keeping with previous observations (3,4,15,20–22). This observation is also consistent with findings in hearts exposed to a pressure overload where the in vitro activity of a number of glycolytic enzymes is increased, as compared with nonhypertrophied hearts (23), and isoenzymes of lactate dehydrogenase (24), enolase (25) and creatine kinase (26) shift toward more anaerobic, fetal forms.
Activation of glucose (and pyruvate) oxidation is expected to lead to a corresponding decrease in glycolytic flux (Pasteur effect) in the presence of a constant or lowered energy demand. Experimentally, however, the effect of DCA on glycolysis in nonischemic and reperfused nonhypertrophied hearts has been variable—sometimes inhibiting glycolysis (9) and sometimes having no effect (11). In the studies reported here, DCA inhibited glycolysis during nonischemic perfusion and reperfusion, but only in hypertrophied hearts (Fig. 2, Table 2). It has been proposed that DCA may directly inhibit glycolysis by reducing the activities of hexokinase and pyruvate kinase (27)—two enzymes in the glycolytic pathway. This possibility was not assessed in the current study. The explanation for the difference between the effect of DCA on glycolysis in control and hypertrophied hearts remains to be determined.
Contractile function and myocardial H+ production.
Despite an acceleration of glycolytic rates in untreated hypertrophied hearts, there was no corresponding increase in the rates of glucose oxidation (Fig. 2 and 3, Table 2). In fact, the rates of glucose oxidation during reperfusion in untreated hypertrophied hearts were lower than those in untreated control hearts. The mechanism(s) responsible for depressed rates of glucose oxidation in untreated hypertrophied hearts are not yet known. Of interest, our very recent experiments suggest that alterations in PDH cannot account entirely for the low rates of glucose oxidation in hypertrophied hearts (28). Regardless of the mechanism, a dramatic uncoupling between glycolysis and glucose oxidation was observed in hypertrophied hearts that was substantially greater than that seen in control hearts. A glucose molecule passing through glycolysis leads to the production of 2 H+, by way of adenosine triphosphate (ATP) hydrolysis, and a molecule of glucose oxidized to carbon dioxide results in no net H+ production (9). As such, H+ production, calculated from rates of glycolysis and glucose oxidation (9), was accelerated in untreated hypertrophied hearts as compared with untreated control hearts before and after ischemia (Fig. 4). Importantly, the absence of differences in glycogen degradation between control and hypertrophied hearts during ischemia indicates that the proton burden arising from glycogen catabolism during no-flow ischemia did not differ between the two groups.
We hypothesize that excess H+ production, arising from alterations in glucose metabolism, is responsible for greater dysfunction of hypertrophied hearts as compared with nonhypertrophied hearts during reperfusion. Accumulation of H+ in the myocardium can interfere with contractile function directly (29). It can also cause influx and intracellular accumulation of Na+ and Ca2+ by means of Na+/H+ and Na+/Ca2+ exchange (6,9,10,30). The influx of Na+ and Ca2+ that occurs secondary to clearance of H+ may reduce contractile function and cardiac efficiency (cardiac work/oxygen consumed) by redirecting ATP toward processes involved in cellular ion transport and away from those involved in contractile function or by leading to myocardial damage, or both (6,9,10,31). Importantly, hypertrophied hearts have alterations in transport processes responsible for Na+ and Ca2+ homeostasis (6). Many of these alterations potentiate the detrimental effects of Na+ and Ca2+ influx and accumulation, especially during reperfusion. In keeping with this scenario, impaired recovery of hypertrophied hearts during reperfusion has been shown to be associated with exaggerated Ca2+ and Na+ overload (2,32).
Dichloroacetate and myocardial H+ production.
In the current study, H+ production in the hypertrophied heart was dramatically reduced by DCA, because glucose oxidation was stimulated and glycolysis was inhibited (Fig. 2 through 4, Table 2). This reduction in H+ production, and its resultant effects on myocardial ion concentrations, was likely a key factor in the functional improvements observed in DCA-treated hypertrophied hearts, particularly during reperfusion. In support of this view, we have shown that a Na+/H+ exchange inhibitor can mimic the effects of DCA in nonhypertrophied hearts perfused under identical conditions (11). Furthermore, we have recently shown that DCA, given at reperfusion, stimulates glucose oxidation, decreases H+ production, increases the rate of recovery of intracellular H+ concentration (pHi) and enhances postischemic recovery of nonhypertrophied hearts (33). However, direct measurement of changes in pHi and Na+ and Ca2+ concentration during reperfusion of hypertrophied hearts, as well as demonstration that inhibitors of Na+/H+ exchange provide similar benefit, will be required to prove that this view is correct. That some variables of contractile function were lower in hypertrophied hearts than in nonhypertrophied hearts in the presence of DCA (Tables 1 through 3) may have resulted from several factors, including lower rates of coronary flow and glucose oxidation as well as alterations in ion pumps and channels (6) in hypertrophied hearts.
Other potential effects of dichloroacetate.
Dichloroacetate may have also improved postischemic function by alternative, but not necessarily mutually exclusive, mechanisms. The beneficial effect of enhanced glucose oxidation may also be due to increases in the intramitochondrial NADH2/oxidized nicotinamide adenine dinucleotide (NAD) ratio, which would thereby increase the mitochondrial oxidative phosphorylation potential (13). The DCA-induced improvement in coronary flow during reperfusion may also have been a contributing factor (Tables 1 through 3).
Conclusions.
We show for the first time, to our knowledge, that DCA normalizes postischemic function of hypertrophied rat hearts in association with stimulation of glucose oxidation and inhibition of glycolysis. These findings support the hypothesis that excess H+ production, arising from high glycolytic rates and low glucose oxidation rates, is responsible for the greater dysfunction of hypertrophied hearts as compared with nonhypertrophied hearts during reperfusion. Furthermore, the data also indicate that pharmacologic modulation of the activity of pyruvate dehydrogenase in hypertrophied hearts may be a therapeutically useful approach to improve function of the hypertrophied heart in the setting of ischemia and reperfusion.
|
Acknowledgments
|
|---|
We gratefully acknowledge the technical assistance of Dean English. We also thank Yulia D’yachkova for assistance with statistical analysis.
|
Footnotes
|
|---|
This study was supported by grants from the Medical Research Council of Canada and the Heart and Stroke Foundation of British Columbia and Yukon. Dr. Allard is a Career Investigator of the Heart and Stroke Foundation of British Columbia and Yukon. Dr. Lopaschuk is a Medical Research Senior Scholar for the Alberta Heritage Foundation.
|
References
|
|---|
1. Anderson PG, Allard MF, Thomas GD, Bishop SP, Digerness SB. Increased ischemic injury but decreased hypoxic injury in hypertrophied rat hearts. Circ Res. 1990;67:948–959[Abstract/Free Full Text]
2. Allard MF, Flint JDA, English JC, et al. Calcium overload during reperfusion is accelerated in isolated hypertrophied rat hearts. J Mol Cell Cardiol. 1994;26:1551–1563[CrossRef][Medline]
3. Schonekess BO, Allard MF, Lopaschuk GD. Recovery of glycolysis and oxidative metabolism during postischemic reperfusion of hypertrophied rat hearts. Am J Physiol. 1996;271:H798–H805
4. Wambolt RB, Henning SL, English DR, Bondy GP, Allard MF. Regression of cardiac hypertrophy normalizes glucose metabolism and left ventricular function during reperfusion. J Mol Cell Cardiol. 1997;29:939–948[CrossRef][Medline]
5. Gaasch WH, Zile MR, Hoshino PK, Weinberg EO, Rhodes DR, Apstein CS. Tolerance of the hypertrophic heart to ischemia: studies in compensated and failing dog hearts with pressure overload hypertrophy. Circulation. 1990;81:1644–1653[Abstract/Free Full Text]
6. Allard MF, Lopaschuk GD. Ischemia and reperfusion injury in the hypertrophied heart. Karmazyn M. Myocardial Ischemia: Mechanisms, Reperfusion, Protection. Basel, Switzerland: Birkhauser Verlag; 1996. p. 423–452
7. Randle PJ. Fuel selection in animals. Biochem Soc Trans. 1986;14:799–806[Medline]
8. Randle PJ, Priestman DA, Mistry SC, Halsall A. Glucose–fatty acid interactions and the regulation of glucose disposal. J Cell Biochem. 1994;5(Suppl):1–11
9. Lopaschuk GD, Wambolt RB, Barr RL. An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acid during aerobic perfusion of ischemic hearts. J Pharmacol Exp Ther. 1993;264:135–144[Abstract/Free Full Text]
10. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions: potential for pharmacological interventions. Cardiovasc Res. 1997;33:243–257[Free Full Text]
11. Liu B, Clanachan AS, Schulz R, Lopaschuk GD. Cardiac efficiency is improved after ischemia by altering both the source and fate of protons. Circ Res. 1996;79:940–948[Abstract/Free Full Text]
12. McVeigh JJ, Lopaschuk GD. Dichloroacetate stimulation of glucose oxidation improves recovery of ischemic rat hearts. Am J Physiol. 1990;259:H1079–H1085
13. Bunger R, Mallet RT, Hartman DA. Pyruvate-enhanced phosphorylation potential and inotropism in normoxic and post-ischemic isolated working heart: near-complete prevention of reperfusion contractile failure. Eur J Biochem. 1989;180:221–233[Medline]
14. Lewandowski ED, White LT. Pyruvate dehydrogenase influences post-ischemic heart function. Circulation. 1995;91:2071–2079[Abstract/Free Full Text]
15. Allard MF, Schönekess B, Henning SL, English DR, Lopaschuk GD. Contribution of oxidative metabolism and glycolysis to ATP production in the hypertrophied heart. Am J Physiol. 1994;267:H742–H750
16. Lopaschuk GD, Belke DD, Gamble J, Itoi T, Schonekess BO. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochem Biophys Acta. 1994;1213:263–276[Medline]
17. Holland BS, Copenhaver MD. An improved sequential rejective Bonferroni procedure. Biometrics. 1987;43:417–423[CrossRef]
18. Stacpoole PW. The pharmacology of dichloroacetate. Metabolism. 1989;38:112–144
19. Whitehouse S, Cooper RH, Randle PJ. Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids. Biochem J. 1974;141:761–774[Medline]
20. Allard MF, Henning SL, Wambolt RB, Granleese SR, English DR, Lopaschuk GD. Glycogen metabolism in the aerobic hypertrophied rat heart. Circulation. 1997;96:676–682[Abstract/Free Full Text]
21. Wambolt RB, Henning SL, English DR, Dyachkova Y, Lopaschuk GD, Allard MF. Glucose utilization and glycogen turnover are accelerated in hypertrophied rat hearts during severe low flow ischemia. J Mol Cell Cardiol. 1999;30:493–502
22. Alaoui-Talibi Z, Guendouz A, Moravec M, Moravec J. Control of oxidative metabolism in volume-overloaded rat hearts: effect of propionyl-L-carnitine. Am J Physiol. 1997;272:H1615–H1624
23. Taegtmeyer H, Overturf ML. Effects of moderate hypertension on cardiac function and metabolism in the rabbit. Hypertension. 1988;11:416–426[Abstract/Free Full Text]
24. Bishop SP, Altschuld RA. Evidence for increased glycolytic metabolism in cardiac hypertrophy and congestive heart failure. Alpert N. Cardiac Hypertrophy. New York: Academic Press; 1971. p. 567–585
25. Keller A, Rouzeau J-D, Farhadian F, et al. Differential expression of  - and ß-enolase genes during rat heart development and hypertrophy. Am J Physiol. 1995;269:H1843–H1851
26. Ingwall JS. The hypertrophied myocardium accumulates the MB-creatine kinase isozyme. Eur Heart J. 1984;5(Suppl F):129–139
27. Anderson JW, Karounos D, Yoneyama T. Dichloroacetate-induced changes in liver of normal and diabetic rats. Proc Soc Exp Biol Med. 1975;148:814–821
28. Lydell CP, Chan AKW, Wambolt RB, Brownsey RW, Bondy GP, Allard MF. Alterations in pyruvate dehydrogenase activity are not responsible for low glucose oxidation in hypertrophied rat hearts during reperfusion. (abstr)Can J Cardiol. 1999;15(Suppl):181D
29. Fabiato A, Fabiato F. Effects of pH on the myofilaments and sarcoplasmic reticulum of skinned cells from cardiac and skeletal muscles. J Physiol. 1978;276:233–255[Abstract/Free Full Text]
30. Tani M, Neely JR. Role of intracellular Na+ in Ca2+ overload and depressed recovery of ventricular function of reperfused ischemic rat hearts: possible role of H+–Na+ and Na+–Ca2+ exchange. Circ Res. 1989;65:1045–1056[Abstract/Free Full Text]
31. Hata K, Takasago T, Saeki A, Nishioka T, Goto Y. Stunned myocardium after rapid correction of acidosis. Circ Res. 1993;74:794–805
32. Golden AL, Bright JM, Pohost GM, Pike MM. Ischemic dysfunction and impaired recovery in hypertensive hypertrophied hearts is associated with exaggerated intracellular sodium accumulation. Am J Hypertens. 1994;7:745–754[Medline]
33. Liu Q, Docherty JC, Rendell J, Clanachan AS, Lopaschuk GD. High levels of fatty acids decrease the rate of recovery of intracellular pH in isolated rat hearts reperfused after ischemia. (abstr)Circulation. 1999;100(Suppl I):I345
This article has been cited by other articles:
|
|
|
|
 
K. M. Pound, N. Sorokina, K. Ballal, D. A. Berkich, M. Fasano, K. F. LaNoue, H. Taegtmeyer, J. M. O'Donnell, and E. D. Lewandowski
Substrate-Enzyme Competition Attenuates Upregulated Anaplerotic Flux Through Malic Enzyme in Hypertrophied Rat Heart and Restores Triacylglyceride Content: Attenuating Upregulated Anaplerosis in Hypertrophy
Circ. Res.,
March 27, 2009;
104(6):
805 - 812.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Nagendran, V. Gurtu, D. Z. Fu, J. R.B. Dyck, A. Haromy, D. B. Ross, I. M. Rebeyka, and E. D. Michelakis
A dynamic and chamber-specific mitochondrial remodeling in right ventricular hypertrophy can be therapeutically targeted
J. Thorac. Cardiovasc. Surg.,
July 1, 2008;
136(1):
168 - 178.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Yang, N. Sambandam, X. Han, R. W. Gross, M. Courtois, A. Kovacs, M. Febbraio, B. N. Finck, and D. P. Kelly
CD36 Deficiency Rescues Lipotoxic Cardiomyopathy
Circ. Res.,
April 27, 2007;
100(8):
1208 - 1217.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Augustus, J. Buchanan, T.-S. Park, K. Hirata, H.-l. Noh, J. Sun, S. Homma, J. D'armiento, E. D. Abel, and I. J. Goldberg
Loss of Lipoprotein Lipase-derived Fatty Acids Leads to Increased Cardiac Glucose Metabolism and Heart Dysfunction
J. Biol. Chem.,
March 31, 2006;
281(13):
8716 - 8723.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. R. DeGrado, M. T. Kitapci, S. Wang, J. Ying, and G. D. Lopaschuk
Validation of 18F-Fluoro-4-Thia-Palmitate as a PET Probe for Myocardial Fatty Acid Oxidation: Effects of Hypoxia and Composition of Exogenous Fatty Acids
J. Nucl. Med.,
January 1, 2006;
47(1):
173 - 181.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Parang, B. Singh, and R. Arora
Metabolic Modulators for Chronic Cardiac Ischemia
Journal of Cardiovascular Pharmacology and Therapeutics,
October 1, 2005;
10(4):
217 - 223.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Saeedi, M. Grist, R. B. Wambolt, A. Bescond-Jacquet, A. Lucien, and M. F. Allard
Trimetazidine Normalizes Postischemic Function of Hypertrophied Rat Hearts
J. Pharmacol. Exp. Ther.,
July 1, 2005;
314(1):
446 - 454.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Burelle, R. B. Wambolt, M. Grist, H. L. Parsons, J. C. F. Chow, C. Antler, A. Bonen, A. Keller, G. A. Dunaway, K. M. Popov, et al.
Regular exercise is associated with a protective metabolic phenotype in the rat heart
Am J Physiol Heart Circ Physiol,
September 1, 2004;
287(3):
H1055 - H1063.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. T. Bloomgarden
Inpatient Diabetes Control: Rationale
Diabetes Care,
August 1, 2004;
27(8):
2074 - 2080.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Galinanes and A. G Fowler
Role of clinical pathologies in myocardial injury following ischaemia and reperfusion
Cardiovasc Res,
February 15, 2004;
61(3):
512 - 521.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.J. Zuurbier
Postischemic Myocardial Metabolism
Seminars in Cardiothoracic and Vascular Anesthesia,
March 1, 2003;
7(1):
59 - 65.
[PDF]
|
|
|
|
|
|
|
C. P Lydell, A. Chan, R. B Wambolt, N. Sambandam, H. Parsons, G. P Bondy, B. Rodrigues, K. M Popov, R. A Harris, R. W Brownsey, et al.
Pyruvate dehydrogenase and the regulation of glucose oxidation in hypertrophied rat hearts
Cardiovasc Res,
March 1, 2002;
53(4):
841 - 851.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. D. Lopaschuk, I. M. Rebeyka, and M. F. Allard
Metabolic Modulation: A Means to Mend a Broken Heart
Circulation,
January 15, 2002;
105(2):
140 - 142.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. T. Smolenski, M. Amrani, J. Jayakumar, P. Jagodzinski, C. C. Gray, A. T. Goodwin, I. A. Sammut, and M. H. Yacoub
Pyruvate/dichloroacetate supply during reperfusion accelerates recovery of cardiac energetics and improves mechanical function following cardioplegic arrest
Eur. J. Cardiothorac. Surg.,
June 1, 2001;
19(6):
865 - 872.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Taegtmeyer
Metabolism--the lost child of cardiology
J. Am. Coll. Cardiol.,
October 1, 2000;
36(4):
1386 - 1388.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. S. Leong, M. Grist, H. Parsons, R. B. Wambolt, G. D. Lopaschuk, R. Brownsey, and M. F. Allard
Accelerated rates of glycolysis in the hypertrophied heart: are they a methodological artifact?
Am J Physiol Endocrinol Metab,
May 1, 2002;
282(5):
E1039 - E1045.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
Top
Abstract
Experimental methods
